Status:
COMPLETED
Brain Imaging Study in Menopausal Women With and Without Major Depressive Disorder
Lead Sponsor:
University of Pennsylvania
Conditions:
Menopause
Depression
Eligibility:
FEMALE
40-70 years
Phase:
PHASE4
Brief Summary
The purpose this study is to measure cortical gama-aminobutyric acid levels (GABA) levels in menopausal women with major depressive disorder and healthy subjects using nuclear magnetic resonance spect...
Eligibility Criteria
Inclusion
- Inclusion criteria for Depressed Patients:
- Aged 40-70 years and able to give voluntary written informed consent.
- Meet DSM-IV criteria for major depression based on a structured clinical interview (SCID).
- Have no medical contraindication to estrogen. (This will include written documentation of a recent normal gynecological evaluation and mammogram).
- A minimum score of 25 on the 25-item Hamilton Depression Rating Scale on initial baseline rating which does not show improvement during the one-week observation period.
- Perimenopausal subjects will be those who have had irregular menses of either \<21 days or \>35 days for the previous six months to one year. Postmenopausal subjects will be those with no menstrual cycles and no hormone therapy for at least one year and serum FSH \>45.
- Exclusion criteria:
- Meeting DSM-IV for any other Axis I disorder.
- A history of serious medical or neurological illness, including (but not limited to) major cardiovascular disease, severe hypertension, intracranial mass lesions, seizure disorder, severe hepatic or renal disease, unstable endocrine or metabolic disease, and unstable hematologic disease.
- A history of moderate to severe endometriosis; milder cases will require subject's Gynecologists permission to participate.
- Use of anticonvulsants or benzodiazepines within the last month.
- Use of psychotropic medication in last week (except as stated above).
- Use of alcohol within last month.
- Current pregnancy (for the perimenopausal subjects).
- Positive urine drug screen.
- Metallic implants.
- Inclusion Criteria for Healthy Subjects:
- No DSM-IV psychiatric or substance abuse diagnosis by structured diagnostic interview (SCID).
- No medical contraindication to estrogen (this will include written documentation of a recent normal gynecological exam with mammogram).
- Matched to depressed patients by age and menopausal status.
- Have no menstrual cycles or hormone therapy for at least one year or irregular menses of either \<21 days or 35 days for the previous six months to one year.
- Exclusion Criteria for Healthy Subjects:
- Medical, neurologic or cerebrovascular disorder (CVA, seizure disorder, etc.).
- Evidence of substance use on urine toxicology screen done upon recruitment.
- Current treatment with psychoactive medication.
- Diabetes controlled by means other than diet.
- Use of alcohol within last month.
- Implanted metallic devices.
- Positive urine drug screen.
Exclusion
Key Trial Info
Start Date :
July 1 1999
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2008
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00626340
Start Date
July 1 1999
End Date
July 1 2008
Last Update
June 1 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yale University
New Haven, Connecticut, United States, 06511